N
Nicolas Mounier
Researcher at Centre Hospitalier Universitaire de Nice
Publications - 198
Citations - 10465
Nicolas Mounier is an academic researcher from Centre Hospitalier Universitaire de Nice. The author has contributed to research in topics: Rituximab & Diffuse large B-cell lymphoma. The author has an hindex of 51, co-authored 197 publications receiving 9352 citations.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht,Bertram Glass,Nicolas Mounier,Devinder Gill,David C. Linch,Marek Trneny,André Bosly,Nicolas Ketterer,Ofer Shpilberg,Hans Hagberg,David D.F. Ma,Josette Brière,Craig H. Moskowitz,Norbert Schmitz +13 more
TL;DR: It is found that patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
Journal ArticleDOI
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles,Nicolas Mounier,Sophie de Guibert,Franck Morschhauser,Chantal Doyen,Jean-François Rossi,Corinne Haioun,Pauline Brice,Beatrice Mahe,Reda Bouabdallah,Bruno Audhuy,Christophe Fermé,Caroline Dartigeas,Pierre Feugier,Catherine Sebban,Luc Xerri,Charles Foussard +16 more
TL;DR: With a 5-year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy.
Journal ArticleDOI
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
Nathalie Mourad,Nicolas Mounier,Josette Brière,Emmanuel Raffoux,Alain Delmer,Alfred C. Feller,Chris J.L.M. Meijer,Jean-François Emile,Reda Bouabdallah,André Bosly,Jacques Diebold,Corinne Haioun,Bertrand Coiffier,Christian Gisselbrecht,Philippe Gaulard +14 more
TL;DR: AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors and portends a poor prognosis even when treated intensively, but is not always lethal.
Journal ArticleDOI
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Catherine Thieblemont,Josette Brière,Nicolas Mounier,Hans-Ullrich Voelker,Wendy Cuccuini,Edouard Hirchaud,Andreas Rosenwald,Andrew Jack,Christer Sundström,Sergio Cogliatti,Philippe Trougouboff,Ludmila Boudova,Loic Ysebaert,Jean Soulier,Catherine Chevalier,Dominique Bron,Norbert Schmitz,Philippe Gaulard,Rémi Houlgatte,Christian Gisselbrecht +19 more
TL;DR: COO remains a major and independent factor in relapsed/refractory diffuse large B-cell lymphoma, with a better response to R-DHAP in GCB-like DLBCL, but needs confirmation by a prospective study.